Prescient Therapeutics Limited Stock
Stocks
PTX
AU000000PTX3
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Australian S.E.
10:10:18 02/09/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.0680 AUD | 0.00% |
|
+1.49% | -19.05% |
| 09:39am | Prescient Therapeutics Hits Dose Optimization Review Milestone in Cancer Drug Study | MT |
| 09-01 | Prescient Therapeutics Limited - Shareholder/Analyst Call |
| Market Cap | 71.5M 51.28M 44.24M 41.67M 37.97M 70.97M 4.84B 493M 191M 2.48B 193M 188M 8.14B | P/E 2025 |
-4.84x | P/E 2026 | -8.94x |
|---|---|---|---|---|---|
| Enterprise Value | 62.68M 44.95M 38.78M 36.53M 33.28M 62.21M 4.25B 432M 168M 2.17B 169M 165M 7.13B | EV / Sales 2025 |
6.54x | EV / Sales 2026 | 16x |
| Free-Float |
89.43% | Yield 2025 * |
-
| Yield 2026 | - |
Last Transcript : Prescient Therapeutics Limited
| 1 week | +1.49% | ||
| Current month | +3.03% | ||
| 1 month | -20.00% | ||
| 3 months | -12.82% | ||
| Current year | -19.05% |
| 1 week | 0.06 |  | 0.07 |
| 1 month | 0.06 | | 0.09 |
| Current year | 0.05 | | 0.1 |
| 1 year | 0.04 | | 0.12 |
| 3 years | 0.04 | | 0.12 |
| 5 years | 0.04 | | 0.3 |
| 10 years | 0.02 | | 0.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 20/01/2025 | |
Melanie Leydin
DFI | Director of Finance/CFO | 53 | - |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
James Campbell
CHM | Chairman | - | 30/03/2025 |
Ellen Feigal
BRD | Director/Board Member | 71 | 15/05/2023 |
Melanie Farris
BRD | Director/Board Member | - | 10/04/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 02/05/23 | Exercice | Chief Executive Officer | 1,148,936 | 0.1430% | ||
| 02/05/23 | Expiration | Chief Executive Officer | 2,351,064 | 0.2926% | ||
| 04/04/23 | Exercice | Chief Executive Officer | 97,692 | 0.0135% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +1.49% | +65.85% | -13.92% | 51.16M | |
| +0.97% | -1.75% | +2.17% | +18.46% | 49.74B | |
| -0.30% | -1.02% | +451.04% | +496.95% | 44.98B | |
| +2.13% | +1.70% | +38.27% | +17.61% | 42.52B | |
| +0.87% | -3.88% | +18.21% | +73.17% | 40.78B | |
| -0.90% | -1.74% | +15.20% | +48.44% | 32.89B | |
| +2.71% | +5.66% | - | - | 17.09B | |
| +1.68% | -3.43% | +24.71% | +116.83% | 16.28B | |
| +1.70% | -1.75% | +12.00% | +28.50% | 14.4B | |
| +3.34% | -1.98% | +78.65% | +39.19% | 13.48B | |
| Average | +1.22% | -2.03% | +78.46% | +91.69% | 27.22B | |
| Weighted average by Cap. | +1.01% | -2.25% | +97.62% | +123.23% |
| 2025 | 2026 | |
|---|---|---|
| Net sales | 4.36M 3.12M 2.7M 2.54M 2.31M 4.32M 295M 30.06M 11.67M 151M 11.73M 11.48M 496M | 3.45M 2.47M 2.14M 2.01M 1.83M 3.43M 234M 23.81M 9.24M 120M 9.29M 9.09M 393M |
| Net income | -7.32M -5.25M -4.53M -4.27M -3.89M -7.27M -496M -50.53M -19.61M -254M -19.72M -19.29M -833M | -7M -5.02M -4.33M -4.08M -3.72M -6.95M -474M -48.32M -18.75M -243M -18.86M -18.45M -797M |
| Net Debt | -6.93M -4.97M -4.29M -4.04M -3.68M -6.88M -469M -47.8M -18.55M -240M -18.65M -18.25M -788M | -8.83M -6.33M -5.46M -5.14M -4.69M -8.76M -598M -60.89M -23.63M -306M -23.77M -23.25M -1B |
Employees
3
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/09/26 | A$0.0680 | 0.00% | 832,037 |
| 01/09/26 | A$0.0680 | +3.03% | 499,072 |
| 31/08/26 | A$0.0660 | -1.49% | 1,296,592 |
| 28/08/26 | A$0.0670 | -1.47% | 681,432 |
| 27/08/26 | A$0.0680 | +1.49% | 840,397 |
- Stock Market
- Stocks
- PTX Stock
Select your edition
All financial news and data tailored to specific country editions
